Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cross Country Healthcare (CCRN) Other financing activities (2016 - 2023)

Historic Other financing activities for Cross Country Healthcare (CCRN) over the last 14 years, with Q2 2023 value amounting to -$501000.0.

  • Cross Country Healthcare's Other financing activities fell 84776.12% to -$501000.0 in Q2 2023 from the same period last year, while for Mar 2024 it was -$501000.0, marking a year-over-year decrease of 46304.35%. This contributed to the annual value of -$508000.0 for FY2023, which is 11569.35% down from last year.
  • According to the latest figures from Q2 2023, Cross Country Healthcare's Other financing activities is -$501000.0, which was down 84776.12% from -$7000.0 recorded in Q1 2023.
  • In the past 5 years, Cross Country Healthcare's Other financing activities ranged from a high of $4.3 million in Q2 2021 and a low of -$860000.0 during Q1 2019
  • For the 5-year period, Cross Country Healthcare's Other financing activities averaged around $645058.8, with its median value being $67000.0 (2022).
  • Per our database at Business Quant, Cross Country Healthcare's Other financing activities skyrocketed by 4325000.0% in 2021 and then plummeted by 84776.12% in 2023.
  • Quarter analysis of 5 years shows Cross Country Healthcare's Other financing activities stood at $3.8 million in 2019, then plummeted by 94.88% to $196000.0 in 2020, then soared by 678.06% to $1.5 million in 2021, then plummeted by 94.89% to $78000.0 in 2022, then crashed by 742.31% to -$501000.0 in 2023.
  • Its Other financing activities stands at -$501000.0 for Q2 2023, versus -$7000.0 for Q1 2023 and $78000.0 for Q4 2022.